U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07522255) titled 'Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders' on March 23.
Brief Summary: This randomized, double-blind, placebo-controlled trial will evaluate whether a 14-day course of rifaximin improves bloating in adult patients with Rome IV functional bowel disorders in whom bloating is the predominant symptom. Eligible participants with irritable bowel syndrome, functional constipation, or functional abdominal bloating/distension and bothersome bloating despite adequate bowel movement management will be assigned in a 1:1 ratio to rifaximin 550 mg three times daily or matching placebo for 2 weeks. The primary endpoin...